BR0012661A - Métodos de tratamento e métodos de triagem de drogas - Google Patents

Métodos de tratamento e métodos de triagem de drogas

Info

Publication number
BR0012661A
BR0012661A BR0012661-6A BR0012661A BR0012661A BR 0012661 A BR0012661 A BR 0012661A BR 0012661 A BR0012661 A BR 0012661A BR 0012661 A BR0012661 A BR 0012661A
Authority
BR
Brazil
Prior art keywords
methods
patient
drug screening
sym
ppar
Prior art date
Application number
BR0012661-6A
Other languages
English (en)
Inventor
Colin Neil Alexander Palmer
Helen Vosper
Charles Roland Wolf
Original Assignee
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dundee filed Critical Univ Dundee
Publication of BR0012661A publication Critical patent/BR0012661A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/5055Cells of the immune system involving macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

"MéTODOS DE TRATAMENTO E MéTODOS DE TRIAGEM DE DROGAS". Um método para evitar ou reduzir o desenvolvimento de células expandidas de macrofágios, ou remover células expandidas, em um paciente, o método compreendendo a administração ao paciente de uma quantidade efetiva de um inibidor de atividade do PPAR<sym>. Um método de evitar ou tratar uma doença vascular associada com a formação de placas e / ou o bloqueamento trombótico dos vasos de sangue em um paciente, o método compreendendo a administração ao paciente de uma quantidade efetiva de um inibidor de atividade PPAR<sym>.
BR0012661-6A 1999-07-23 2000-07-19 Métodos de tratamento e métodos de triagem de drogas BR0012661A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9917405.4A GB9917405D0 (en) 1999-07-23 1999-07-23 Methods of treatment and drug screening methods
PCT/EP2000/006986 WO2001007066A2 (en) 1999-07-23 2000-07-19 Ppar delta inhibitors for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
BR0012661A true BR0012661A (pt) 2002-04-09

Family

ID=10857874

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012661-6A BR0012661A (pt) 1999-07-23 2000-07-19 Métodos de tratamento e métodos de triagem de drogas

Country Status (29)

Country Link
EP (1) EP1200114B1 (pt)
JP (1) JP2003505058A (pt)
KR (1) KR20020012323A (pt)
CN (1) CN1364087A (pt)
AR (1) AR027832A1 (pt)
AT (1) ATE430577T1 (pt)
AU (1) AU6825900A (pt)
BR (1) BR0012661A (pt)
CA (1) CA2378462A1 (pt)
CO (1) CO5280202A1 (pt)
CY (1) CY1109255T1 (pt)
CZ (1) CZ2002247A3 (pt)
DE (1) DE60042161D1 (pt)
DK (1) DK1200114T3 (pt)
ES (1) ES2326785T3 (pt)
GB (1) GB9917405D0 (pt)
HK (1) HK1046094B (pt)
HU (1) HUP0201966A3 (pt)
IL (1) IL147363A0 (pt)
MX (1) MXPA02000880A (pt)
MY (1) MY140626A (pt)
NO (1) NO20020326L (pt)
NZ (1) NZ573856A (pt)
PL (1) PL205747B1 (pt)
PT (1) PT1200114E (pt)
SI (1) SI1200114T1 (pt)
TR (2) TR200200211T2 (pt)
WO (1) WO2001007066A2 (pt)
ZA (1) ZA200200542B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2417005A1 (en) * 2000-07-20 2002-01-31 Bristol Myers Squibb Company Regulators of ppar.delta.(.beta.) and their use in the treatment of obesity and insulin resistance
AU2002243778A1 (en) * 2001-02-02 2002-09-19 Smithkline Beecham Corporation Treatment of ppar mediated diseases
GB0103809D0 (en) 2001-02-16 2001-04-04 Univ Dundee Methods
EP1511483A4 (en) * 2002-03-27 2009-03-18 Smithkline Beecham Corp PROCESSING METHODS USING LXR MODULATORS
GB0302446D0 (en) * 2003-02-03 2003-03-05 Imp College Innovations Ltd Screening for modulators of fat storage
US20070037882A1 (en) * 2003-04-22 2007-02-15 Astellas Pharma Inc. Remedy for cerebral neurodegenerative diseases using ppar agonist
US20070237740A1 (en) * 2004-09-27 2007-10-11 Vical, Inc. Formulations and Methods for Treatment of Inflammatory Diseases
DE102006033394A1 (de) * 2006-07-13 2008-01-17 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verfahren zum Auffinden von antiatherosklerotischen Substanzen
RU2444518C2 (ru) * 2007-01-08 2012-03-10 Сеул Нэшнл Юниверсити Индастри Фаундейшн ПРОИЗВОДНОЕ ТИАЗОЛА КАК PPARδ ЛИГАНД И ФАРМАЦЕВТИЧЕСКИЙ, КОСМЕТИЧЕСКИЙ И ДИЕТИЧЕСКИЙ ПИЩЕВОЙ ПРОДУКТ, СОДЕРЖАЩИЙ ЕГО
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
WO1997028149A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
CN1234029A (zh) * 1996-08-27 1999-11-03 盐野义制药株式会社 色烯-3-羚酸衍生物
DE69739828D1 (de) * 1996-12-11 2010-05-12 Dana Farber Cancer Inst Inc Methoden und pharmazeutische Zusammensetzungen zur Inhibition des Tumorwachstums
WO1998043081A1 (en) * 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
DK1016714T3 (da) * 1997-06-27 2003-08-11 Ono Pharmaceutical Co Nyt plasmid DNA indeholdende reportergen DNA og anvendelse af samme
AU8355998A (en) * 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases

Also Published As

Publication number Publication date
TR200501763T2 (tr) 2005-08-22
CY1109255T1 (el) 2014-07-02
AU6825900A (en) 2001-02-13
PT1200114E (pt) 2009-07-09
AR027832A1 (es) 2003-04-16
PL205747B1 (pl) 2010-05-31
DE60042161D1 (de) 2009-06-18
SI1200114T1 (sl) 2009-10-31
NO20020326L (no) 2002-03-20
PL364749A1 (en) 2004-12-13
EP1200114B1 (en) 2009-05-06
WO2001007066A3 (en) 2001-08-09
CZ2002247A3 (cs) 2002-11-13
KR20020012323A (ko) 2002-02-15
CO5280202A1 (es) 2003-05-30
MY140626A (en) 2010-01-15
TR200501763T1 (tr) 2009-03-23
JP2003505058A (ja) 2003-02-12
NO20020326D0 (no) 2002-01-22
WO2001007066A2 (en) 2001-02-01
HUP0201966A2 (en) 2002-09-28
HK1046094A1 (en) 2002-12-27
TR200200211T2 (tr) 2002-06-21
CN1364087A (zh) 2002-08-14
CA2378462A1 (en) 2001-02-01
GB9917405D0 (en) 1999-09-22
IL147363A0 (en) 2002-08-14
MXPA02000880A (es) 2003-07-14
NZ573856A (en) 2010-06-25
EP1200114A2 (en) 2002-05-02
HK1046094B (zh) 2009-10-02
ES2326785T3 (es) 2009-10-20
HUP0201966A3 (en) 2005-01-28
ATE430577T1 (de) 2009-05-15
ZA200200542B (en) 2003-07-30
DK1200114T3 (da) 2009-08-03

Similar Documents

Publication Publication Date Title
PT955880E (pt) Metodo e aparelho para tratamento de arritmias cardiacas sem alvo discreto
UA41989C2 (uk) Фармацевтична композиція у вигляді гелю для лікування захворювань шкіри та спосіб лікування інфікованої шкіри
ZA989385B (en) Methods for treating hypercoagulable states or acquired protein C deficiency.
BR0309890A (pt) Composição farmacêutica contendo plasma sanguìneo, ou soro sanguìneo utilizada no tratamento de lesões, bem como seu método e processo de aplicação
NO963568D0 (no) Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse
SE9702860D0 (sv) New use
HK1076379A1 (en) Use of a composition comprising anti-vla-1 antibody for the preparation of a pharmaceutical composition for the treatment of pulmonary fibrosis
CY1109255T1 (el) Ppar δελτα αναστολεις για την αντιμετωπιση καρδιαγγειακων νοσων
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
BR9912773A (pt) Processo e aparelho para o tratamento tópico de tecido doente e processo para o tratamento de doenças em vasos do sistema circulatório
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
PT811376E (pt) Utilizacao de alcanoil l-carnitinas para o fabrico de um medicamento para o tratamento de doencas inflamatorias dos intestinos
ATE271881T1 (de) Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
AU2003283227A1 (en) Method and means for the treatment of vascular and cardiac diseases
PT1063978E (pt) Metodo de tratamento de dor de neuroma
WO2001008669A3 (en) Therapeutic agents for lymphoedema
Sadovsky Glucosamine and knee pain associated with osteoarthritis
KR940003550A (ko) 노인성 치매 예방 및 치료방법
EP1321146A3 (en) Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
WO2004035030A3 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
RU97121914A (ru) Способ лечения костных кист
UA31780A (uk) Спосіб пластики загальної жовчної протоки
WO2003072737A3 (en) Biological inhibitions induced by contact inhibitory factor
UA31749A (uk) Спосіб лікування множинних оклюзійно-стенотичних уражень артерій нижньої кінцівки

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O ART. 24, ART. 8O COMBINADO COM ART. 13, ART. 10 E ART. 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.